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 Abstract
Primary male neuroendocrine breast carcinoma (NEBC) is extremely rare neoplasm. This type of breast 
carcinoma has been reported sporadically in men. The authors of this article found described only 
two cases neuroendocrine breast carcinoma (NEBC) in men. Most neuroendocrine tumors are mainly 
located in the gastrointestinal tract and are heterogeneous group of rare tumors with positive reaction to 
neuroendocrine makers in at least 50% of cells. Neuroendocrine breast cancer was first time recognized 
by the WHO in 2003. Epidemiology, histogenesis and biology of this cancer are still unknown. There is 
no standard treatment protocol in neuroendocrine breast carcinoma.
The authors of this article presented a case of a 65-year-old Caucasian man who was treated in the 
hospital because of primary neuroendocrine breast cancer. The authors performed a literature review 
on primary neuroendocrine breast cancer diagnosis and treatment. 
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 Streszczenie
Pierwotny neuroendokrynny rak piersi (NEBC) u mężczyzn jest niezwykle rzadkim nowotworem. 
Ten typ raka sutka występuje bardzo rzadko u mężczyzn. Autorzy tego artykułu znaleźli opisane 
tylko dwa przypadki NEBC u mężczyzn. Większość guzów neuroendokrynnych zlokalizowane 
jest głównie w przewodzie pokarmowym i są one niejednorodną grupą rzadkich nowotworów 
z pozytywną reakcją na markery neuroendokrynne w co najmniej 50% komórek. Neuroendokryn-
ny rak piersi został pierwszy raz uznany przez WHO w 2003 roku. Epidemiologia, histogeneza 
i biologia tego nowotworu jest nadal nieznana. Nie ma standardowego protokołu leczenia 
neuroendokrynnego raka piersi.
Autorzy tego artykułu przedstawili przypadek 65-letniego mężczyzny rasy białej, który został 
przyjęty do szpitala z powodu NEBC. Autorzy dokonali przeglądu piśmiennictwa na temat dia-
gnostyki i leczenia NEBC. 
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Introduction
Primary male neuroendocrine breast carcinoma (NEBC) 
is extremely rare neoplasm [1, 2]. This type of breast 
carcinoma has been reported sporadically in men [1]. 
Most neuroendocrine tumors are located in the gastroin-
testinal tract and are heterogeneous group of rare tumors 
with positive reaction to neuroendocrine makers in at 
least 50% of cells [3, 4]. Neuroendocrine breast cancer 
was first time recognized by the WHO in 2003 [3, 4]. Ep-
idemiology, histogenesis and biology of this cancer are 
still unknown. There is no standard treatment protocol 
in neuroendocrine breast carcinoma due to rarity of this 
disease [1, 3].
Case report
A 65-year-old Caucasian man was referred to the 
Department of Surgical Oncology Hospital Ministry of 
Internal Affairs with Warmia and Mazury Oncology 
Center in Olsztyn due to breast tumor discovered in pal-
pable examination. The size of this tumor in ultrasound 
was 31 x 28 mm and it was located in the nipple of 
the left breast. The tumor was confirmed by imaging 
ultrasonography and mammogram studies. The mam-
mography found the tumor diameter of about 30 mm, 
BIRADS V (Fig. 1). The patient had no other symptoms; 
there was no history of weight loss and loss of appetite. 
The patient was treated chronically for benign prostatic 
hyperplasia (BPH). He had no surgeries and there was 
no history of carcinoma in patient family. Blood test and 
other routine hematological examinations and biochemi-
cal tests were within normal limits.
Palpation for the nipple revealed palpable tumor, ap-
proximately 3 cm in diameter, painless, movable relative 
to the surrounding tissues. The patient suffered from 
gynecomastia of both breasts. Lymph nodes located 
in the left axilla were enlarged — a diameter of 15 mm.
In the Department of Surgical Oncology the patient 
had open surgical biopsy of the left breast tumor (Fig. 2). 
Figure 1. Primary male neuroendocrine breast carcinoma 
(NEBC) on mammography picture
Figure 2. Gynecomastia of both breasts. The scar after open 
surgery biopsy of the neuroendocrine tumor located 
in the left breast
Figure 3. Neuroendocrine tumor cells in the male breast. He-
matoxylin-Eosin staining, 100×
Figure 4. Neuroendocrine tumor cells in the male breast. He-
matoxylin-Eosin staining, 200×
Next day after the surgical biopsy, the patient left the 
department in good condition.
Pathological diagnosis showed neuroendocrine tu-
mor well-differentiated (Fig. 3 and 4). Tumor cells were 
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This cancer occurs more often in white women than in 
black women [7]. The authors of this article found de-
scribed only two cases of neuroendocrine breast car-
cinoma (NEBC) in men [1, 8]. This neoplasm was first 
time described by Feyrter and Harmann in 1963 [9]. 
This type of breast cancer was first time recognized 
by the WHO in 2003 and defined as the expression of 
neuroendocrine markers in more than 50% of tumor 
cells [3, 4]. WHO divided neuroendocrine carcinomas 
into three subtypes:
 — neuroendocrine tumor, well-differentiated;
 — neuroendocrine carcinoma, poorly differentiated/ 
/small cell carcinoma and
 — invasive breast carcinoma with neuroendocrine dif-
ferentiation [3, 4].
Pathologists rely on using two most sensitive and spe-
cific neuroendocrine markers: chromogranin A or B and 
synaptophysin [10]. More than 80% of neuroendocrine 
breast carcinomas have positive progesterone receptor 
(PR) or estrogen receptor (ER) [11]. Her-2 expression is 
nonexistent or rarely present in neuroendocrine tumors 
[7, 12]. The same situation was in the case described by 
the authors of the following article. Tumor cells were 
positive to chromogranin and synaptophysin, but also 
positive for progesterone and estrogen receptors.
Prognosis seems to correlate with the stage of dis-
ease [10]. The majority of tumors are up to 20 mm and 
it means that patients are in early stage breast cancer. 
There are no specific recommendation regarding surgical, 
chemotherapeutical or radiotherapeutical management. 
Patients should be treated similarly to invasive ductal 
carcinoma, depending on clinical stage and location of 
the tumor [13]. It is estimated that about 50% of the re-
gional lymph nodes are involved at the time of diagnosis, 
similarly as in our case. 
Adjuvant radiation and chemotherapy plays import-
ant role in systemic treatment of neuroendocrine breast 
carcinomas [14]. It is important to choose the ideal type 
of cytotoxic therapy. In the literature there are some 
examples reported: paclitaxel alone; adriamycin and 
cytoxan or cisplatin; etoposimide and carboplatin or cis-
Figure 5. Tumor cells are positive to chromogranin (100×)
Figure 6. Tumor cells are positive to synaptophysin (100×)
chromogranin (+++), synaptophysin (++), ER and PR 
positive in 95%, Ki67 (+) in 20%, E-cadherin (++) and 
Her2 (0) (Fig. 5 and 6).
The patient was re-admitted to The Department of 
Surgical Oncology to be subjected to amputation of the 
left breast with axillary lymphadenectomy left-sided. 
The patient underwent surgery and left the Department 
of Surgical Oncology three days after surgery.
Histopathology examination showed metastases in 
11 among 17 removed lymph nodes in the left armpit 
(Fig. 7). The patient was referred for further systemic 
treatment — chemotherapy.
Discussion
Primary neuroendocrine breast carcinoma (NEBC) is 
extremely rare type of breast tumor in male population 
and has been reported sporadically even in female [1, 2]. 
It is estimated that NEBC occurs up to 0.5% of all breast 
cancer specimens [2, 5]. According to Ogawa et al., it 
accounts for less than 0.1% of all breast cancers and less 
than 1% of all neuroendocrine tumors [6]. This neoplasm 
in the majority of cases has been described in women. 
Figure 7. Removed enlarged axillar lymph nodes
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platin. Also estrogen and progesterone receptors positive 
patients should have hormonal therapy [15]. In our case, 
ER and PR receptors were positive and HER-2 negative so 
hormonal therapy was accordingly prescribed.
The primary neuroendocrine breast carcinomas 
may give distant metastasis [6, 7]. The most often 
distant metastases are observed in bones and liver [7]. 
Other distant metastases were observed in imaging 
studies in lungs, mediastinal lymph nodes, adrenal 
glands and fallopian tubes [7].
The treatment of neuroendorcine breast carcinomas 
should be conducted in oncological centers and patients 
need multimodal therapy. Surgery is still very important 
part of treating this neoplasm. 
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